Antibody persistence upto 5 years after primary immunization and booster with an inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children

References

• Pearce JC, Learoyd TP, Langendorf BJ, Logan JG. Japanese encephalitis: the vectors, ecology and potential for expansion. J Travel Med. 2018;25(suppl_1):S16–6. doi:10.1093/jtm/tay009.
   PubMedGoogle Scholar
• Oliveira ARS, Cohnstaedt LW, Strathe E, Etcheverry L, McVey DS, Piaggio J, Cernicchiaro N. Meta-analyses of Japanese encephalitis virus infection, dissemination, and transmission rates in vectors. Am J Trop Med Hyg. 2018;98(3):883–90. doi:10.4269/ajtmh.17-0622.
   PubMed Web of Science ®Google Scholar
• Kumari R, Kumar K, Rawat A, Singh G, Yadav NK, Chauhan LS. First indigenous transmission of Japanese encephalitis in urban areas of National Capital Territory of Delhi, India. Trop Med Int Health. 2013;18(6):743–49. doi:10.1111/tmi.12104.
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhaori G, Vene S, Shen K, Zhou Y, Magnius LO, Wahren B, Linde A. Viral etiology of acute childhood encephalitis in Beijing diagnosed by analysis of single samples. Pediatr Infect Dis J. 1996;15(11):1018–24. doi:10.1097/00006454-199611000-00017.
   PubMed Web of Science ®Google Scholar
• Campbell GL, Hills SL, Fischer M, Jacobson JA, Hoke CH, Hombach JM, Marfin AA, Solomon T, Tsai TF, Tsu VD, et al. Estimated global incidence of Japanese encephalitis: a systematic review. Bull World Health Organ. 2011;89(10):766–74, 774A–774E. doi:10.2471/BLT.10.085233.
   PubMed Web of Science ®Google Scholar
• Heffelfinger JD, Li X, Batmunkh N, Grabovac V, Diorditsa S, Liyanage JB, Pattamadilok S, Bahl S, Vannice KS, Hyde TB, et al. Japanese encephalitis surveillance and immunization - Asia and Western Pacific regions, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(22):579–83. doi:10.15585/mmwr.mm6622a3.
   PubMed Web of Science ®Google Scholar
• Caldwell JP, Chen LH, Hamer DH. Evolving epidemiology of Japanese encephalitis: implications for vaccination. Curr Infect Dis Rep. 2018;20(9):30. doi:10.1007/s11908-018-0635-8.
   PubMed Web of Science ®Google Scholar
• Wang H, Liang G. Epidemiology of Japanese encephalitis: past, present, and future prospects. Ther Clin Risk Manag. 2015;11:435–48. Published 2015 Mar 19. doi:10.2147/TCRM.S51168.
   PubMed Web of Science ®Google Scholar
• Global Vaccine Safety. Information sheet observed rate of vaccine reactions Japanese encephalitis. Geneva (Switzerland): World Health Organization. 2019 Oct 5 [accessed 2019 Nov 22] https://www.who.int/vaccine_safety/initiative/tools/vaccinfosheets/en/ .
   Google Scholar
• Libao Z, Xin Z, Xutao W, Ligang W, Hui L, Miaomiao L. Adverse reaction and immunogenicity of inactivated Japanese encephalitis vaccine prepared on Vero cells. Chin J Biological. 2009;8:809–11.
   Google Scholar
• Chanthavanich P, Limkittikul K, Sirivichayakul C, Chokejindachai W, Hattasingh W, Pengsaa K, Surangsrirat S, Srisuwannaporn T, Kaewma B, Yoksan S, et al. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children. Hum Vaccin Immunother. 2018;14(4):900–05. doi:10.1080/21645515.2017.1414763.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Code of Federal Regulations Title 21, Sec.600.80. Postmarketing reporting of adverse experiences, 2017. [ accessed 19 November 2019] http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=600.80 .
   Google Scholar
• Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. Vaccine. 2005;23(45):5205–11. doi:10.1016/j.vaccine.2005.07.002.
   PubMed Web of Science ®Google Scholar
• Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857–72. doi:10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E.
   PubMed Web of Science ®Google Scholar
• Chokephaibulkit K, Sirivichayakul C, Thisyakorn U, Pancharoen C, Boaz M, Bouckenooghe A, Feroldi E. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: immune responses in children. Vaccine. 2016;34(46):5664–69. doi:10.1016/j.vaccine.2016.09.018.
   PubMed Web of Science ®Google Scholar
• Kosalaraksa P, Watanaveeradej V, Pancharoen C, Capeding MR, Feroldi E, Bouckenooghe A. Long-term immunogenicity of a single dose of Japanese encephalitis chimeric virus vaccine in toddlers and booster response 5 years after primary immunization. Pediatr Infect Dis J. 2017;36(4):e108–e113. doi:10.1097/INF.0000000000001494.
   PubMed Web of Science ®Google Scholar
• Capeding MR, Alberto ER, Bouckenooghe A, Laot TM, Chansinghakul D, Monfredo C, Machabert T, Feroldi E. Five-year antibody persistence following a Japanese encephalitis chimeric virus vaccine (JE-CV) booster in JE-CV–primed children in the Philippines. J Infect Dis. 2018;217(4):567–71. doi:10.1093/infdis/jix601.
   PubMed Web of Science ®Google Scholar
• Kadlecek V, Borja-Tabora CF, Eder-Lingelbach S, Gatchalian S, Kiermayr S, Sablan B Jr, Kundi M, Taucher C, Dubischar KL. Antibody persistence up to 3 years after primary immunization with inactivated Japanese encephalitis vaccine IXIARO in Philippine children and effect of a booster dose. Pediatr Infect Dis J. 2018;37(9):e233–e240. doi:10.1097/INF.0000000000002124.
   PubMed Web of Science ®Google Scholar
• Yun KW, Lee HJ, Park JY, Cho HK, Kim YJ, Kim KH, Kim NH, Hong YJ, Kim DH, Kim HM, et al. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine. Vaccine. 2018;36(11):1398–404. doi:10.1016/j.vaccine.2018.01.075.
   PubMed Web of Science ®Google Scholar
• Nealon J, Taurel AF, Yoksan S, Moureau A, Bonaparte M, Quang LC, Capeding MR, Prayitno A, Hadinegoro SR, Chansinghakul D, et al. Serological evidence of Japanese encephalitis virus circulation in Asian children from dengue-endemic countries. J Infect Dis. 2019;219(3):375–81. doi:10.1093/infdis/jiy513.
   PubMed Web of Science ®Google Scholar
• Ferguson M, Johnes S, Li L, Heath A, Barrett A. Effect of genomic variation in the challenge virus on the neutralization titres of recipients of inactivated JE vaccines - report of a collaborative study on PRNT50 assays for Japanese encephalitis virus (JE) antibodies. Biologicals. 2008;36:111–16. doi:10.1016/j.biologicals.2007.07.002.
   PubMed Web of Science ®Google Scholar
• WHO Expert Committee on Biological Standardization. Fifty-eighth report. Geneva (Switzerland): WHO Technical Report Series; 2011. Report No: 963.
   Google Scholar